Eribulin Mesylate

甲磺酸艾日布林

Report date: 2026/04/10 20:01:49
NMEFirst In Class

Base Information

Drug NameEribulin Mesylate
Drug Alias Nameeribulinum甲磺酸艾立布林Eribulin Mesilate甲磺酸艾瑞布林甲磺酸艾利布林 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitors
TargetsTubulin
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerHormone-Resistant Prostate Neoplasms +[34] 
Global Approved IndicationsBreast NeoplasmsLiposarcoma
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2010/11/15
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOhsu Knight Cancer InstituteUniversity Of Southern CaliforniaNational Cancer Institute +[8] 
Inactive CompaniesDana-Farber Cancer InstituteEisai LtdThe University Of Oklahoma +[9] 
Active IndicationsBrain metastasesSolid tumoursUrologic Neoplasms +[17] 
Inactive IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsUrinary Bladder Neoplasms +[17] 

Other Information

ATC CodeL01XX41
Related LinksWikipediaDrugBankKEGG